9 research outputs found
Visible-Light Photoswitchable Benzimidazole Azo-Arenes as beta-Arrestin2-Biased Selective Cannabinoid 2 Receptor Agonists
Acknowledgements The authors would like to acknowledge Dr. Andrea Holme for excellent technical support and the Iain Fraser Cytometry Centre (University of Aberdeen) for providing access to their equipment. The authors would like to thank Dr. Matthias Scheiner for his contributions towards the development of the calcium mobilization assay and Dr. ValĂŠrie Jahns for her efforts towards faster automated analysis of the obtained results. Nick Verhavert is acknowledged for his assistance with the NanoBiTÂŽ assay. Diego Rodriguez-Soacha is acknowledged for establishing the rCB1R radioligand binding assay in our laboratory. Special thanks to Dr. Rangan Maitra and RTI International for providing the G16 coupled hCB1 and hCB2 CHO-K1 cell lines. The authors thank Nadine YurdagĂźl-Hemmrich and Annette Hannawacker for excellent technical support. This project was funded by the German Research Foundation (Deutsche Forschungsgemeinschaft under DFG DE1546/10-1). J. N. Hislopâs financing support was given by NHS Grampian. The research visit of S. A. M. SteinmuĚller in Dr. Hislopâs laboratory was funded by the Elite Network of Bavaria (grant N° K-BM-2013-247). J. Fender and A. Tutov were supported by the International Doctoral Program âReceptor Dynamicsâ funded within the framework of the Elite Network of Bavaria (grant N° K-BM-2013- 247). M. H. Deventer was funded by the Research FoundationFlanders (FWO; grant 1S54521N).Peer reviewe
Bridging the Binding Sites : Dualsteric Ligands for the Cannabinoid 2 Receptor (CB2R)
Acknowledgements This project was financially supported by the German Research Foundation (Deutsche Forschungsgemeinschaft under DFG DE1546/10-1). Gratitude is expressed to the International Doctorate Program âReceptor Dynamicsâ of the Elite Network of Bavaria (ENB) for financial support of A.T. and S.A.M.S. (grant No. K-BM-2013-247). Y.A.R. was granted a scholarship by the German Academic Exchange Service (Deutscher Akademischer Austauschdienst, DAAD) program âResearch stays for university academics and scientists.â D.A.R.-S. was awarded a Ph.D. scholarship by the DAAD. J.N.H. was financially supported by NHS Grampian. Furthermore, the authors thank Professor Dr. Kristina Lorenz (Institute of Pharmacology and Toxicology, University of WĂźrzburg) for enabling them to conduct in vitro experiments in her laboratory. Open access funding enabled and organized by Projekt DEAL.Peer reviewedPublisher PD
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer's Disease Mouse Model.
We present the synthesis and characterization of merged human butyrylcholinesterase (hBChE) inhibitor/cannabinoid receptor 2 (hCB2R) ligands for the treatment of neurodegeneration. In total, 15 benzimidazole carbamates were synthesized and tested for their inhibition of human cholinesterases, also with regard to their pseudoirreversible binding mode and affinity toward both cannabinoid receptors in radioligand binding studies. After evaluation in a calcium mobilization assay as well as a β-arrestin 2 (βarr2) recruitment assay, two compounds with balanced activities on both targets were tested for their immunomodulatory effect on microglia activation and regarding their pharmacokinetic properties and blood-brain barrier penetration. Compound 15d, containing a dimethyl carbamate motif, was further evaluated in vivo, showing prevention of Aβ25-35-induced learning impairments in a pharmacological mouse model of Alzheimer's disease for both short- and long-term memory responses. Additional combination studies proved a synergic effect of BChE inhibition and CB2R activation in vivo
Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter
Purpose: A new PET radiotracer 18F-AF78 showing great potential for clinical application has been reported recently. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Although many efforts have been made to develop NET inhibitors as antidepressants, systemic investigations of the structure–activity relationships (SARs) of NET-targeting radiotracers have rarely been performed. Methods: Without changing the phenethylguanidine pharmacophore and 3-fluoropropyl moiety that is crucial for easy labeling, six new analogs of 18F-AF78 with different meta-substituents on the benzene-ring were synthesized and evaluated in a competitive cellular uptake assay and in in vivo animal experiments in rats. Computational modeling of these tracers was established to quantitatively rationalize the interaction between the radiotracers and NET. Results: Using non-radiolabeled reference compounds, a competitive cellular uptake assay showed a decrease in NET-transporting affinity from meta-fluorine to iodine (0.42 and 6.51 µM, respectively), with meta-OH being the least active (22.67 µM). Furthermore, in vivo animal studies with radioisotopes showed that heart-to-blood ratios agreed with the cellular experiments, with AF78(F) exhibiting the highest cardiac uptake. This result correlates positively with the electronegativity rather than the atomic radius of the meta-substituent. Computational modeling studies revealed a crucial influence of halogen substituents on the radiotracer–NET interaction, whereby a T-shaped π–π stacking interaction between the benzene-ring of the tracer and the amino acid residues surrounding the NET binding site made major contributions to the different affinities, in accordance with the pharmacological data. Conclusion: The SARs were characterized by in vitro and in vivo evaluation, and computational modeling quantitatively rationalized the interaction between radiotracers and the NET binding site. These findings pave the way for further evaluation in different species and underline the potential of AF78(F) for clinical application, e.g., cardiac innervation imaging or molecular imaging of neuroendocrine tumors
Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter
A new PET radiotracer 18F-AF78 showing great potential for clinical application has been reported recently. It belongs to a new generation of phenethylguanidine-based norepinephrine transporter (NET)-targeting radiotracers. Although many efforts have been made to develop NET inhibitors as antidepressants, systemic investigations of the structureâactivity relationships (SARs) of NET-targeting radiotracers have rarely been performed. Methods: Without changing the phenethylguanidine pharmacophore and 3-fluoropropyl moiety that is crucial for easy labeling, six new analogs of 18F-AF78 with different meta-substituents on the benzene-ring were synthesized and evaluated in a competitive cellular uptake assay and in in vivo animal experiments in rats. Computational modeling of these tracers was established to quantitatively rationalize the interaction between the radiotracers and NET. Results: Using non-radiolabeled reference compounds, a competitive cellular uptake assay showed a decrease in NET-transporting affinity from meta-fluorine to iodine (0.42 and 6.51 ÂľM, respectively), with meta-OH being the least active (22.67 ÂľM). Furthermore, in vivo animal studies with radioisotopes showed that heart-to-blood ratios agreed with the cellular experiments, with AF78(F) exhibiting the highest cardiac uptake. This result correlates positively with the electronegativity rather than the atomic radius of the meta-substituent. Computational modeling studies revealed a crucial influence of halogen substituents on the radiotracerâNET interaction, whereby a T-shaped ĎâĎ stacking interaction between the benzene-ring of the tracer and the amino acid residues surrounding the NET binding site made major contributions to the different affinities, in accordance with the pharmacological data. Conclusion: The SARs were characterized by in vitro and in vivo evaluation, and computational modeling quantitatively rationalized the interaction between radiotracers and the NET binding site. These findings pave the way for further evaluation in different species and underline the potential of AF78(F) for clinical application, e.g., cardiac innervation imaging or molecular imaging of neuroendocrine tumors
Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter
Optimization of Artificial Siderophores as Ga-Complexed PET Tracers for In Vivo Imaging of Bacterial Infections.
The diagnosis of bacterial infections at deep body sites benefits from noninvasive imaging of molecular probes that can be traced by positron emission tomography (PET). We specifically labeled bacteria by targeting their iron transport system with artificial siderophores. The cyclen-based probes contain different binding sites for iron and the PET nuclide gallium-68. A panel of 11 siderophores with different iron coordination numbers and geometries was synthesized in up to 8 steps, and candidates with the best siderophore potential were selected by a growth recovery assay. The probes [68Ga]7 and [68Ga]15 were found to be suitable for PET imaging based on their radiochemical yield, radiochemical purity, and complex stability in vitro and in vivo. Both showed significant uptake in mice infected with Escherichia coli and were able to discern infection from lipopolysaccharide-triggered, sterile inflammation. The study qualifies cyclen-based artificial siderophores as readily accessible scaffolds for the in vivo imaging of bacteria
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimerâs Disease Mouse Model
We present the synthesis and characterization of merged
human butyrylcholinesterase
(hBChE) inhibitor/cannabinoid receptor 2 (hCB2R) ligands for the treatment of neurodegeneration.
In total, 15 benzimidazole carbamates were synthesized and tested
for their inhibition of human cholinesterases, also with regard to
their pseudoirreversible binding mode and affinity toward both cannabinoid
receptors in radioligand binding studies. After evaluation in a calcium
mobilization assay as well as a β-arrestin 2 (βarr2) recruitment
assay, two compounds with balanced activities on both targets were
tested for their immunomodulatory effect on microglia activation and
regarding their pharmacokinetic properties and bloodâbrain
barrier penetration. Compound 15d, containing a dimethyl
carbamate motif, was further evaluated in vivo, showing prevention
of Aβ25â35-induced learning impairments in
a pharmacological mouse model of Alzheimerâs disease for both
short- and long-term memory responses. Additional combination studies
proved a synergic effect of BChE inhibition and CB2R activation
in vivo
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimerâs Disease Mouse Model
We present the synthesis and characterization of merged
human butyrylcholinesterase
(hBChE) inhibitor/cannabinoid receptor 2 (hCB2R) ligands for the treatment of neurodegeneration.
In total, 15 benzimidazole carbamates were synthesized and tested
for their inhibition of human cholinesterases, also with regard to
their pseudoirreversible binding mode and affinity toward both cannabinoid
receptors in radioligand binding studies. After evaluation in a calcium
mobilization assay as well as a β-arrestin 2 (βarr2) recruitment
assay, two compounds with balanced activities on both targets were
tested for their immunomodulatory effect on microglia activation and
regarding their pharmacokinetic properties and bloodâbrain
barrier penetration. Compound 15d, containing a dimethyl
carbamate motif, was further evaluated in vivo, showing prevention
of Aβ25â35-induced learning impairments in
a pharmacological mouse model of Alzheimerâs disease for both
short- and long-term memory responses. Additional combination studies
proved a synergic effect of BChE inhibition and CB2R activation
in vivo